Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04
Published . Updated .
The average one-year price target for Immix Biopharma (NASDAQCM:IMMX) has been revised to $25.04 / share. This is an increase of 10.16% from the prior estimate of $22.73 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not cons
Directly affected
- IMMX Immix Biopharma
Named in this report.
Indirectly affected
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Immix Biopharma (NASDAQCM:IMMX) has been revised to $25.04 / share. This is an increase of 10.16% from the prior estimate of $22.73 dated September 11, 2026. These figures represent aggregate analyst t…
Source: Nasdaq Markets
How far Immix Biopharma (IMMX) has moved since 2 Oct 2026
Since the first closing price after “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04,” Immix Biopharma (IMMX) is -19.01%. The S&P 500 fund (SPY) is -1.08% over the same days, a -17.93% difference versus the market.
Who gains and who loses around Immix Biopharma (IMMX)
Companies tied to this story
- IMMX Immix Biopharma
Immix Biopharma (IMMX) is linked, with no stored direction, high confidence in the 2 Oct 2026 story “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04.” Reason on file: The reported development directly names IMMIX BIOPHARMA INC in the headline; GA resolved that company to IMMX
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
In “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04.” Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
For “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04,” Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence. Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04.” Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
In “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04.” Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Immix Biopharma (IMMX)
“Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04” (2 Oct 2026) reaches Immix Biopharma (IMMX) through this story.
Immix Biopharma (IMMX) is on the page because The reported development directly names IMMIX BIOPHARMA INC in the headline; GA resolved that company to IMMX
T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is here too. Its reason reads: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Immix Biopharma (IMMX)
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99. IMMX traded between 7.95 and 12.88 across 20 sessions. The latest close on file is 8.22.
What the saved facts support for Immix Biopharma (IMMX)
46 out of 100
“Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.